Product Development


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">AACR data suggest Agenus&#x2019; next-generation CTLA-4 blocker may expand responding patient group</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1ef7l34r60"></h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Lauren Martz, Senior Editor</span>
</div><div class="date">April 12, 2021 10:21 PM GMT</div></div></div></div>


Agenus Inc.

AGEN1181

Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

Agenus’ latest clinical data for AGEN1181 support the idea that Fc engineering can expand the population of patients who respond to checkpoint inhibitors.  While many companies are

Featured Analysis

Articles

Current Editions

Data Graphics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

Events

My Workspace

Company Overview

Management

Editorial & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home